Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017

Lung cancer is a leading cause of death due to cancer in many countries, including Japan [1]. Non-small-cell lung cancer (NSCLC) accounts for 85 –90% of lung cancers [2]. Approximately 70% of NSCLC patients are diagnosed with advanced or metastatic disease that is not amenable to surgical resection, and the prognosis remains poor [3]. However, in the previous two decades several new antineoplastic agents have been approved for the treatmen t of NSCLC in Japan (Figure 1). In the 1990s, several cytotoxic agents (CAs) were approved, and the role of chemotherapy in the treatment of stage IV NSCLC was established by 1995 [4].

Source: Lung Cancer - March 20, 2019 Category: Cancer & Oncology Authors: Natsuki Takano, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Masafumi Saiki, Yosuke Kawashima, Tomoyo Oguri, Kakeru Hisakane, Ken Uchibori, Shingo Nishikawa, Satoru Kitazono, Noriko Yanagitani, Fumiyoshi Ohyanagi, Atsushi Horiike, Akihiko Gemma, Makoto Nish Source Type: research